


#25E
977
PATENT 2/12/02
Docket No. 399632000420

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231, on December 5, 2001.


Susan B. Lynch

TECH CENTER 1600/2900

FEB 04 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ralph KUBO, et al.

Examiner: M. DiBrino

Group Art Unit: 1644

Application No.: 09/017,524

Filing Date: 3 February 1998

For: HLA BINDING PEPTIDES AND THEIR
USES

AMENDMENT

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated October 5, 2001, for which a response was due on November 5, 2001. Accordingly, a petition for extension of time for one month and required fees are enclosed.

Please enter the following Sequence Listing, amendments and remarks.

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new pages 1-26 in the above-captioned application. A computer-readable copy (CRF) of the Sequence Listing accompanies this response.

Amendments

In the Claims

Please replace claim number 91, with the following rewritten claim:

-- 91. (New) An isolated antigenic HLA-A3 binding peptide derived from a HIV-1 protein having the following formula:

Xaa₁Xaa₂Xaa₃Xaa₄Xaa₅Xaa₆Xaa₇Xaa₈Xaa₉Xaa₁₀

wherein Xaa₂ is Leu, Met, Ile, Val, Ser, or Thr, and Xaa₁₀ is Lys or Arg, and said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said decapeptide. (SEQ ID NO. 104)--